T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells.
about
The heat-stable antigen determines pathogenicity of self-reactive T cells in experimental autoimmune encephalomyelitisMelanoma Peptide Vaccines.Modulation of NKT cell development by B7-CD28 interaction: an expanding horizon for costimulation.Effect of B7.1 costimulation on T-cell based immunity against TAP-negative cancer can be facilitated by TAP1 expressionTumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapyHeat shock proteins: the fountainhead of innate and adaptive immune responses.AAV2-mediated in vivo immune gene therapy of solid tumours.Principles of tumor immunosurveillance and implications for immunotherapy.Ablation of Cbl-b provides protection against transplanted and spontaneous tumors.Antigen-presenting cell engineering. The molecular toolboxAutologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain.Susceptibility to tumors induced by polyoma virus is conferred by an endogenous mouse mammary tumor virus superantigen.CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells.Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity.Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation.Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo.B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism.B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo.Costimulation by B7 modulates specificity of cytotoxic T lymphocytes: a missing link that explains some bystander T cell activation.Expression of B7 costimulation molecules by colorectal cancer cells reducestumorigenicity and induces anti-tumor immunity.Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responsesB7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge.Expression of B7 co-stimulatory molecules by B16 melanoma results in a natural killer cell-dependent local anti-tumour response, but induces T-cell-dependent systemic immunity only against B7-expressing tumours.Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytesPriming of immune responses against transporter associated with antigen processing (TAP)-deficient tumours: tumour direct priming.Local gene therapy of solid tumors with GM-CSF and B7-1 eradicates both treated and distal tumors.Can co-stimulated tumor immunity be therapeutically efficacious?Induction of an antitumour adaptive immune response elicited by tumour cells expressing de novo B7-1 mainly depends on the anatomical site of their delivery: the dose applied regulates the expansion of the response.Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse.Gene transfer of the Co-stimulatory molecules B7-1 and B7-2 enhances the immunogenicity of human renal cell carcinoma to a different extent.The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response.The complexities of T-cell co-stimulation: CD28 and beyond.Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cellsCo-expression of B7-1 with Interleukin-12 Enhances Vaccine-induced Antitumour Immunity in Experimental Myeloma.Tumor cells cotransduced with B7.1 and gamma-IFN induce effective rejection of established parental tumor.B7.1 expression by the weakly immunogenic F98 rat glioma does not enhance immunogenicity.Tumour rejection by gene transfer of 4-1BB ligand into a CD80(+) murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells.A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction
P2860
Q28591104-A3B1B91D-922B-4E35-A9D6-C1530D94B315Q30305778-6F9523CA-CE25-4B56-8F16-0F153A8AE3D6Q30845162-EDF7F81B-0C8C-42CA-A942-070A305838C8Q33486534-652A0034-371E-40F5-B6B4-D44528BBAC44Q34137777-41AD6C33-F879-46C7-B55B-CC50ED45C83BQ34145113-D03C6464-BD2F-44F1-A743-1A8FEFF3C52EQ34468330-E006D0C4-2712-4A5B-8E24-BEA5C3609806Q35043113-42B5D3FD-240A-48D8-88F1-AC03CFE70600Q35664087-EE5750B3-E50B-401E-B23A-CC97BCD60DBEQ35773889-42151859-464B-4442-8B7E-B9563320FE84Q36004284-A972AF33-5195-4B18-9D0F-656DADC9D811Q36364745-B5698621-D002-49FD-B4ED-DEC6954BF089Q36364787-C3FFCAB0-F957-4848-AAFE-8172BB18C791Q36366075-E3F8F616-7FAE-40BC-A3C6-38D9B8A5F4D1Q36366130-CF2A3B59-C78E-4FC1-AE8A-BECA699ED8EBQ36367209-DB163CB8-04A7-4DF9-BDAF-D0B68C141EE5Q36367821-916225AC-F6D2-4E23-BA94-E8BF24D3310BQ36370918-D5CDFBA6-B7EC-40CC-9323-BB5A30AFE26FQ36376380-37A0524E-D1E1-4CAD-94F8-BD17461A05DBQ36380864-73BB8390-1A80-48FC-95B6-057F94B0CFF1Q36396919-CADB31AB-30ED-4C0C-9F57-5DEBBE228B70Q36831746-9DC59623-CD2A-46AC-A48C-0BE9D6C44B1AQ37396545-7459F856-83CE-4A74-8F12-5F4246739D3EQ39710346-B3539B56-8C2A-469F-9380-83EFC6640C48Q39752699-35402C11-B34E-421D-AA94-FC56557BA20CQ39753154-4BD32684-6F5D-49C0-9313-E94E2E0FC126Q40250415-7A951375-B40D-4836-A723-B3BAF6BDB1A8Q40433269-A9EE0B72-E169-4431-A18C-B77117EE7A86Q40614567-CB5E2490-16E9-40CF-BE54-BC67DB141C64Q40827760-C7F48B8D-B302-4B1C-AE6C-31C6BB5B42ACQ40935387-8F3E0FD3-5B8B-4246-977D-6AE82EC0C93FQ41332070-9CE1A9E4-877F-4734-813B-A59D0547779BQ41332130-675FDCF6-B82E-429B-8192-1935D6B38FBFQ41807177-E13A6AC2-56AE-446F-B4A5-A01C78161324Q45856286-9D14ACBC-B2F7-4BEB-8CF0-443EC2EFC43FQ45861119-37F7FDE9-5897-4199-96AD-20551B384C69Q45868892-998DA6F6-0A82-4931-A218-16ABC22EE531Q45873362-22E53222-03D6-4D40-B296-C764036063F2Q52689094-6FA5DF1F-BE0A-4294-9796-0A1C098FDB33Q59061007-97799C72-D1D4-4D3A-BF26-E9330EF4ACB1
P2860
T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
T cell costimulation by B7/BB1 ...... function of antitumor T cells.
@ast
T cell costimulation by B7/BB1 ...... function of antitumor T cells.
@en
type
label
T cell costimulation by B7/BB1 ...... function of antitumor T cells.
@ast
T cell costimulation by B7/BB1 ...... function of antitumor T cells.
@en
prefLabel
T cell costimulation by B7/BB1 ...... function of antitumor T cells.
@ast
T cell costimulation by B7/BB1 ...... function of antitumor T cells.
@en
P2093
P2860
P356
P1476
T cell costimulation by B7/BB1 ...... function of antitumor T cells
@en
P2093
P2860
P304
P356
10.1084/JEM.179.4.1205
P407
P50
P577
1994-04-01T00:00:00Z